Overview
Pharmaceutical companies make important, life-saving medicines. But that
shouldn't give them license to drive up drug prices, ignore the risks of
harmful side effects, or block needed reforms in Massachusetts or in Congress. Consider:
• Pharmaceutical companies use
direct-to-consumer ads to sell their latest, most expensive drugs. The
industry claims that these ads help to educate consumers, but a MASSPIRG analysis of FDA records for the years 2001 to 2005 found that the
ads for 150 different drugs were false or misleading.
• Merck,
the manufacturer of Vioxx, continued to market its painkiller to
doctors and patients years after the company had substantial evidence
of increased the risk of heart problems. FDA researchers estimate that,
in less than 5 years, Vioxx may have caused as many as 139,000 heart
attacks and strokes.
• The industry continues to use
unscrupulous marketing techniques to influence prescriptions that
doctors write, including fancy meals, travel junkets and money—in the
form of “consultant” fees.
• More than three million seniors are
falling into the doughnut hole—Medicare’s prescription drug coverage
gap. Seniors have to keep paying their monthly premiums, but Medicare does not pay for their drugs until seniors pay $3,600 in out-of-pocket expenses for their medicines. When Congress created the Medicare
prescription drug benefit, the pharmaceutical industry and its
lobbyists inserted a provision that prohibits the program from
negotiating bulk-rate discounts for drugs.
MASSPIRG is working to require drug companies to fully disclose studies
and information about the safety and effectiveness of their drugs, to enable
the FDA to better crack down on misleading drug advertisements, to rein in
inappropriate gifts to doctors, to prevent illegal prescription drug practices, and to
allow Congress to negotiate drug discounts for the Medicare program.
Prescription
Action Litigation Project: MASSPIRG joins consumer groups
in suing pharmaceutical companies for price gouging and anti-competitive practices. Read more.
